CLPP内肽酶调节剂的专利视角：2019-至今
Patenting perspective of modulators of ClpP endopeptidase: 2019-present
DOI 原文链接
用sci-hub下载
如无法下载，请从 Sci-Hub 选择可用站点尝试。
影响因子:4.6
分区:医学2区 / 药物化学2区 药学2区
发表日期:2024 Nov
作者:
Zhenyu Wang, Liqing He, Ziheng Fan, Youfu Luo
DOI:
10.1080/13543776.2024.2404233
摘要
CLPP是一种高度保守的丝氨酸蛋白酶，在维持细菌细胞和人线粒体的蛋白稳态方面起着至关重要的作用。几项研究表明，CLPP作为药物靶标的潜力，其中包括抑制剂和激活剂在内，在治疗一系列疾病（例如耐药细菌，恶性癌和脂肪肝病）方面表现出了希望，这提供了与Clpp调节剂有关的概述，该评论概述了与Clpp调节剂有关的五年概述，并详细介绍了他们的主张，并详细介绍了Spapeitic sepapeic oppepapeic opepapeicutic。专利信息的来源包括欧洲专利局，中国专利局和美国专利局的数据库，同时通过PubMed访问了相关的研究文章。有关CLPP调制器的专利数量正在上升，反映了相关研究的进步。通过总结和概述相关专利，我们旨在激发研究人员的进一步兴趣，最终导致基于CLPP调节剂的有效药物开发。与CLPP功能障碍相关的广泛疾病强调了CLPP调节剂可以满足各种治疗需求的潜力。
Abstract
ClpP is a highly conserved serine protease that plays a crucial role in maintaining protein homeostasis in both bacterial cells and human mitochondria. Several studies have demonstrated the potential of ClpP as a drug target, with ClpP modulators, including both inhibitors and activators, showing promise in treating a range of conditions such as drug-resistant bacteria, malignant cancers, and fatty liver disease.This review provides an overview of patents related to ClpP modulators filed over the last five years, detailing their claims and therapeutic applications. The sources of patent information included databases of the European Patent Office, the China Patent Office and the U.S.A. patent Office, while relevant research articles were accessed through PubMed.The number of patents concerning ClpP modulators is on the rise, reflecting advancements in related research. By summarizing and outlining relevant patents, we aim to stimulate further interest among researchers, ultimately leading to the development of effective drugs based on ClpP modulators. The broad spectrum of diseases associated with ClpP dysfunction underscores the potential for ClpP modulators to address a wide range of therapeutic needs.